Search

Enter keywords, a title or a report id number below.

Order by Fax Ask a Question Printer Friendly PDF Brochure

Electronic (PDF)

Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the title.

EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00
Site License

Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access the title.

EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00
Enterprisewide

Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access the title.

EURO€ 1,153.00USD$ 1,500.00GBP£ 970.00AUD$ 1,467.00JPY¥ 148,099.00SEK 9 849,00CHF 1'414.00CAD$ 1,528.00

Live Chat Live Help Software for Website

Dementia - Pipeline Review, H1 2012

Global Markets Direct, June 2012, Pages: 103

Dementia – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Dementia - Pipeline Review, H1 2012', provides an overview of the Dementia therapeutic pipeline. This report provides information on the therapeutic development for Dementia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dementia. 'Dementia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Dementia.
- A review of the Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Dementia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Dementia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Dementia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Dementia Therapeutic Products under Development, Key Players in Dementia Therapeutics, Dementia Pipeline Overview, Dementia Pipeline, Dementia Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Dementia Overview
Therapeutics Development
An Overview of Pipeline Products for Dementia
Dementia Therapeutics under Development by Companies
Dementia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Dementia Therapeutics – Products under Development by Companies
Dementia Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Dementia Therapeutics Development
Abbott Laboratories
GlaxoSmithKline plc
Sylentis
Astellas Pharma Inc.
Eisai Co., Ltd.
Kowa Company, Ltd.
Merz GmbH & Co. KGaA
Neuren Pharmaceuticals Limited
NeuroSearch A/S
WhanIn Pharmaceutical Co., Ltd.
SYGNIS Pharma AG
Allon Therapeutics Inc.
MediPost Co., Ltd.
e-Therapeutics plc
Oryzon
Noscira, S.A.
BIOALVO S.A.
BioArctic Neuroscience AB
Sparsha Pharma International Pvt. Ltd.
Tautatis Incorporated
Stelic Institute & Co.
Varinel, Inc.
Dementia – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
NYPTA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SB-742457 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK239512 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP0777 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BLV0703 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aricept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KIBRA Modulators - Drug Profile
Product Description
Mechanism of Action
R&D Progress
G Family Inhibitor For Dementia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neurostem - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ETX6765 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NSD-761 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ABT-560 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NNZ-2591 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VAR-10100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Memantine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Donepezil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TTT-3002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Donepezil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methylphenidate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Memantine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Memantine Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tolcapone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Memantine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
K-828-AB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Dementia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
WIN-026 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PD and AD Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Namisol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paroxetine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Second Generation Davunetide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ladostigil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PD0805 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Edaravon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MRZ 99030 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dementia Therapeutics – Drug Profile Updates
Dementia Therapeutics – Discontinued Products
Dementia Therapeutics - Dormant Products
Dementia – Product Development Milestones
Featured News & Press Releases
May 15, 2012: Adamas Announces Successful End-Of-Phase II Meeting With FDA For Arimenda
Feb 13, 2012: Allon's Data Safety Monitoring Board Recommends To Continue Pivotal Clinical Trial Of Davunetide
Nov 08, 2011: NeuroSearch Publishes MermaiHD Study In The Lancet Neurology
Oct 20, 2011: Allon Therapeutics Successfully Completes Patient Enrollment In Phase II/III Pivotal Trial Of Davunetide
Jun 30, 2011: NeuroSearch Provides Update On Clinical Development Program For Huntexil
Feb 23, 2011: Intellectual Property High Court of Japan Rules to Maintain Aricept Patent Term Extension in Relation to Severe Alzheimer's Dementia
Jul 24, 2010: Eisai Announces U.S. FDA Approval for New Higher Dose Aricept 23mg Tablet for the Treatment of Moderate-to-severe Alzheimer’s Disease
Jul 22, 2010: Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KGaA Settle NAMENDA Patent Litigation
Jul 22, 2010: Mylan Announces Settlement Agreement for Namenda
Jul 09, 2010: SeneXta Therapeutics SA Announces The Successful Completion Of Phase I Study With SNX-001
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Dementia, H1 2012
Products under Development for Dementia – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Abbott Laboratories, H1 2012
GlaxoSmithKline plc, H1 2012
Sylentis, H1 2012
Astellas Pharma Inc., H1 2012
Eisai Co., Ltd., H1 2012
Kowa Company, Ltd., H1 2012
Merz GmbH & Co. KGaA, H1 2012
Neuren Pharmaceuticals Limited, H1 2012
NeuroSearch A/S, H1 2012
WhanIn Pharmaceutical Co., Ltd., H1 2012
SYGNIS Pharma AG, H1 2012
Allon Therapeutics Inc., H1 2012
MediPost Co., Ltd., H1 2012
e-Therapeutics plc, H1 2012
Oryzon, H1 2012
Noscira, S.A., H1 2012
BIOALVO S.A., H1 2012
BioArctic Neuroscience AB, H1 2012
Sparsha Pharma International Pvt. Ltd., H1 2012
Tautatis Incorporated, H1 2012
Stelic Institute & Co., H1 2012
Varinel, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Dementia Therapeutics – Drug Profile Updates
Dementia Therapeutics – Discontinued Products
Dementia Therapeutics – Dormant Products
Dementia Therapeutics – Dormant Products (Contd..1)
Dementia Therapeutics – Dormant Products (Contd..2)

List of Figures
Number of Products under Development for Dementia, H1 2012
Products under Development for Dementia – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network

Viewing report

• ORDER BY FAX

• REGISTER

• SELECT SITE CURRENCY

Dementia - Pipeline Review, H1 2012

Global Markets Direct, June 2012, Pages: 103

Customers who bought this item also bought

For enquiries please call us on: